Author: Danny Sullivan – Longevity.Technology
Regulator’s decision based on NMN’s investigation for use as a pharmaceutical drug – sparks immediate response from the Council for Responsible Nutrition.
The United States Food & Drug Administration has said popular longevity supplement ingredient beta-nicotinamide mononucleotide (NMN) cannot be sold as a dietary supplement in the US. Recently published letters to prospective new suppliers indicate that the reason for this is because NMN “has been authorized for investigation as a new drug”.
The Council for Responsible Nutrition (CRN), the US trade association for the dietary supplement and functional food industry, has responded expressing its “dismay” at the ruling.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/U5VZBBJ5SBJARD5TTCJHHDF6VM.jpg "FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study")
